Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 473-820-3
CAS number: -
A literature-based toxicokinetic assessment was carried out.
The data presented in this dossier only allows a qualitative assessment
of the toxicokinetic behaviour of the substance for registration. The
data was awarded a reliability score of 4 in accordance with the
criteria for assessing data quality set forth by Klimisch et al. (1997).
However, a couple of significant conclusions can be made.
Hyperform™ HPN-20E has a molecular weight of 210 g/mol. It is a poorly
soluble solid (solubility 296 mg/L), with over 87 % of the particles
being >100 µm in size. The melting point is > 360 °C and the substance
has a very low vapour pressure. The logPow is -2.56. The substance
appears stable in solution at pH 4, 7 and 9. The substance is
The substance is poorly soluble in water and even less soluble in
lipids. Thus it is unlikely to be absorbed orally or dermally. Although
a poorly soluble particulate, the particle size is such that very little
is likely to be inhaled and retained.
The substance is essentially unlikely to be distributed and, if
administered parenterally, is likely to remain at the site of
Given the solubility profile of the material it is unlikely to become
available for metabolism.
Given the solubility profile of the substance, it is not likely to be
available for excretion. If particles lodge in the alveolus following
inhalation, they will be dealt with largely as insoluble particulates,
and if the substance is administered orally it is likely to appear in
Given the solubility profile and particle size, the substance is
unlikely to be absorbed orally or dermally, and is unlikely to be
inhaled and retained. Given the solubility of the material, it is also
unlikely to become available for metabolism or excretion. If particles
lodge in the alveolus following inhalation, they will be dealt with
largely as insoluble particulates, and if the substance is administered
orally it is likely to appear in faeces unabsorbed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again